China Pioneer Pharma Holdings Limited
HKEX:1345.HK
2.01 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 1,566.673 | 1,556.04 | 1,434.82 | 1,332.037 | 1,315.978 | 1,624.305 | 2,153.935 | 1,790.275 | 1,460.899 | 1,540.398 | 1,272.247 | 958.723 | 717.831 | 570.647 |
Cost of Revenue
| 898.434 | 775.574 | 662.791 | 724.071 | 636.182 | 991.881 | 1,432.514 | 1,196.858 | 998.322 | 1,048.449 | 885.6 | 651.978 | 522.129 | 404.557 |
Gross Profit
| 668.239 | 780.466 | 772.029 | 607.966 | 679.796 | 632.424 | 721.421 | 593.417 | 462.577 | 491.949 | 386.647 | 306.745 | 195.702 | 166.09 |
Gross Profit Ratio
| 0.427 | 0.502 | 0.538 | 0.456 | 0.517 | 0.389 | 0.335 | 0.331 | 0.317 | 0.319 | 0.304 | 0.32 | 0.273 | 0.291 |
Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 112.106 | 82.082 | 72.327 | 65.463 | 84.184 | 74.353 | 66.557 | 73.37 | 66.745 | 55.043 | 33.565 | 28.67 | 18.333 | 15.565 |
Selling & Marketing Expenses
| 422.604 | 467.744 | 517.203 | 443.739 | 446.803 | 399.655 | 370.272 | 277.488 | 135.378 | 152.652 | 101.76 | 92.087 | 68.652 | 63.811 |
SG&A
| 534.696 | 548.277 | 584.793 | 534.841 | 541.324 | 482.768 | 436.829 | 350.858 | 202.123 | 207.695 | 135.325 | 120.757 | 86.985 | 79.376 |
Other Expenses
| 0 | 4.833 | 2.748 | 2.915 | 8.538 | 8.747 | 5.283 | 3.952 | 5.25 | 4.772 | 1.335 | 0.793 | 0.594 | 0.334 |
Operating Expenses
| 488.03 | 496.55 | 574.592 | 518.971 | 543.339 | 541.608 | 428.381 | 323.966 | 276.788 | 210.256 | 113.459 | 109.374 | 79.09 | 71.084 |
Operating Income
| 180.209 | 232.189 | 187.236 | 73.125 | 138.472 | 149.656 | 284.592 | 242.559 | 260.454 | 284.254 | 251.322 | 214.643 | 125.144 | 102.133 |
Operating Income Ratio
| 0.115 | 0.149 | 0.13 | 0.055 | 0.105 | 0.092 | 0.132 | 0.135 | 0.178 | 0.185 | 0.198 | 0.224 | 0.174 | 0.179 |
Total Other Income Expenses Net
| 0.239 | 55.452 | 12.763 | 22.217 | 9.997 | -42.542 | 3.921 | 11.412 | -53.659 | 13.728 | 21.164 | -7.804 | 6.481 | -5.251 |
Income Before Tax
| 180.448 | 294.497 | 201.447 | 95.342 | 148.469 | 107.114 | 309.317 | 282.35 | 206.795 | 304.688 | 272.486 | 206.839 | 123.093 | 96.882 |
Income Before Tax Ratio
| 0.115 | 0.189 | 0.14 | 0.072 | 0.113 | 0.066 | 0.144 | 0.158 | 0.142 | 0.198 | 0.214 | 0.216 | 0.171 | 0.17 |
Income Tax Expense
| 51.451 | 64.547 | 60.629 | 43.852 | 44.646 | 22.343 | 28.71 | 43.726 | 34.294 | 43.737 | 36.732 | 21.122 | 26.081 | 21.805 |
Net Income
| 145.718 | 235.296 | 142.633 | 52.448 | 104.627 | 84.597 | 278.925 | 237.445 | 174.302 | 261.718 | 238.372 | 186.369 | 95.675 | 70.435 |
Net Income Ratio
| 0.093 | 0.151 | 0.099 | 0.039 | 0.08 | 0.052 | 0.129 | 0.133 | 0.119 | 0.17 | 0.187 | 0.194 | 0.133 | 0.123 |
EPS
| 0.12 | 0.2 | 0.12 | 0.043 | 0.086 | 0.068 | 0.22 | 0.18 | 0.13 | 0.2 | 0.23 | 0.19 | 0.097 | 0.072 |
EPS Diluted
| 0.12 | 0.2 | 0.12 | 0.043 | 0.086 | 0.068 | 0.22 | 0.18 | 0.13 | 0.2 | 0.23 | 0.19 | 0.097 | 0.072 |
EBITDA
| 201.876 | 245.378 | 199.964 | 104.786 | 161.314 | 157.742 | 292.911 | 255.739 | 243.63 | 291.855 | 287.645 | 219.093 | 131.111 | 103.841 |
EBITDA Ratio
| 0.129 | 0.158 | 0.139 | 0.061 | 0.112 | 0.097 | 0.136 | 0.143 | 0.19 | 0.189 | 0.199 | 0.227 | 0.178 | 0.182 |